PERSPECTIVES

A Practical Guide to Third-Party Cyber Risk Management

Cyber risk is no longer contained within your organisation. Today’s most damaging breaches don’t start with you, they start with the third parties you...

Learn More

PERSPECTIVES

Compliance Implications of Anthropic’s Dispute with the Pentagon

In late February 2026, the US Department of Defense (DoD) designated the artificial intelligence (AI) company Anthropic a supply chain risk, a first for...

Learn More

EVENTS & WEBINARS

Human Rights Due Diligence and Modern Slavery: Global Expectations for Compliance Programs

Human rights and modern slavery risks are receiving heightened regulatory and enforcement attention across global supply chains.[...]

Learn More

PERSPECTIVES

Key Takeaways from our Webinar: Managing Human Rights and Corruption Risks Across Life Sciences Third Parties

Key Takeaways from our Webinar: Managing Human Rights and Corruption Risks Across Life Sciences Third Parties In Partnership with Ethics and Compliance Switzerland. [...]

Learn More

EVENTS & WEBINARS

Anti-Corruption, Fraud & Global Compliance For Life Sciences

We’re proud to sponsor 21st Annual Anti-Corruption, Fraud & Global Compliance for Life Sciences conference on May 5–6, 2026! They’ll be sharing how Ethixbase360...

Learn More

EVENTS & WEBINARS

Ownership Transparency and Sanctions Risk: Building a Defensible UBO Program

Ultimate beneficial ownership (UBO) has moved from a background AML requirement to a central control for sanctions compliance, export controls, and third-party risk management. [...]

Learn More

EVENTS & WEBINARS

Human Rights Due Diligence and Modern Slavery: APAC and Global Compliance Expectations

Human rights and modern slavery risks are receiving increasing regulatory and enforcement attention across global supply chains. Governments are moving beyond transparency-led approaches toward...

Learn More

EVENTS & WEBINARS

Reputational Risk and Third-Party Exposure: Compliance Lessons from the Epstein Files

Recent disclosures linked to the Epstein case have reignited public scrutiny around reputational risk, third-party relationships, and the hidden vulnerabilities that sit beyond formal...

Learn More

PERSPECTIVES

Key Takeaways from Our London Roundtable: Human Rights Due Diligence in Pharma

We recently hosted a pharma-focused roundtable in partnership with Norton Rose Fulbright at their London office, bringing together senior risk and compliance professionals from...

Learn More